Please assess the completion status of the following clinical trial:

Trial Title: Triple Combinations Against Hookworm Infections in Lao

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by parents and/or legal representative; and a verbal assent (children \<12 years) or signed assent (children ≥12 years), according to Lao regulations.~* Able and willing to be examined by a study physician at the beginning of the study.~* Able and willing to provide two stool samples at the beginning (baseline) and two to three weeks after treatment (follow-up).~* Positive for hookworm eggs in the stool.~* Absence of major systemic illnesses, e.g. diabetes, severe anemia as assessed by a medical doctor, upon initial clinical assessment.~* No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease.~* No recent anthelminthic treatment (within past 4 weeks).~* No known allergy to study medications (e.g. albendazole, mebendazole, pyrantel pamoate, oxantel pamoate).~* Negative pregnancy test (girls ≥12 years)~Exclusion Criteria:~* No written informed consent by parents and/or legal representative and no verbal assent (children \<12 years) or signed assent (children ≥12 years).~* Presence of major systemic illnesses, e.g. diabetes, severe anemia as assessed by a medical doctor, upon initial clinical assessment.~* History of acute or severe chronic disease.~* Recent use of anthelminthic drug (within past 4 weeks).~* Attending other clinical trials during the study.~* Negative diagnostic result for hookworm eggs in the stool.~* Positive pregnancy test (girls ≥12 years)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole triple combi (Type: ACTIVE_COMPARATOR): Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
- Pyrantel pamoate double combi (Type: EXPERIMENTAL): Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
- Albendazole double combi (Type: EXPERIMENTAL): Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
- Mebendazole triple combi (Type: EXPERIMENTAL): Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).